Sarepta Investors: Important Notice Regarding Class Action Lawsuit Deadlines

Legal Warning for Sarepta Investors

Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential legal claims against Sarepta Therapeutics, Inc. This investigation is crucial for shareholders who may have faced significant financial losses due to the company's actions. Investors who acquired Sarepta stock between June 22, 2023, and June 24, 2025, are encouraged to take immediate action as an important deadline approaches: August 25, 2025. This date marks the cutoff for investors aiming to serve as lead plaintiffs in a federal securities class action lawsuit against Sarepta.

Background Information

The inquiry involves allegations that Sarepta and its executives may have violated securities laws by issuing false or misleading statements. Investors contend that the company did not adequately disclose critical safety risks associated with their drug, ELEVIDYS. Several serious adverse events and deaths concerning this treatment have raised significant questions about the company's transparency and compliance with safety regulations.

Allegations Against Sarepta

Details of the allegations suggest that:
1. ELEVIDYS posed considerable safety risks to patients.
2. The clinical trials for ELEVIDYS failed to detect severe side effects that could jeopardize patient health.
3. As a result of these failures, recruitment for and administration of ELEVIDYS treatments had to be halted, drawing scrutiny from regulatory authorities.
4. Sarepta's communication regarding the efficacy and safety of ELEVIDYS lacked a reasonable basis, misleading investors about the drug's approval conditions.

On March 18, 2025, Sarepta announced a grim safety update indicating that a patient had died after treatment with ELEVIDYS. This announcement triggered significant repercussions in the company's stock valuation, with the price plunging to $73.54, a steep decline of 27.44% on the same day. Following this, on April 4, 2025, authorities in the European Union requested a review of the death, leading to the halting of recruitment in several clinical trials for ELEVIDYS, resulting in another significant drop in stock price to $54.43.

Further compounding issues, by June 15, 2025, a second patient had died due to acute liver failure attributed to ELEVIDYS treatment. Consequently, Sarepta suspended shipments for non-ambulatory patients as the company reassessed its protocols. This news caused an alarming 42.12% drop in stock value, bringing the closing price to $20.91 on June 15. Moreover, on June 24, 2025, the FDA issued a Safety Communication regarding the deaths and ongoing investigations into ELEVIDYS, further shaking investor confidence as the stock fell again to $17.46 on June 25, 2025.

Next Steps for Investors

Investors who believe they have been negatively impacted by Sarepta's actions should act swiftly to safeguard their rights. The lead plaintiff designation is vital because it determines who will guide the litigation process on behalf of the affected investors. To pursue this opportunity, you can reach out to Faruqi & Faruqi directly. You may also share any pertinent information regarding Sarepta's conduct, whether you are a whistleblower, a former employee, or a concerned shareholder.

For more details on how to participate in the class action lawsuit or to report information, visit Faruqi & Faruqi's website or call partner Josh Wilson at 877-247-4292.

This is a pivotal moment for many investors, and ensuring your voice is heard may be critical to achieving a fair resolution. Remember, your participation in the class action could be vital to holding Sarepta accountable for the alleged negligence. As the deadline of August 25, 2025, looms closer, don't delay in taking the necessary steps to protect your investment.